News

Daiichi Sankyo announced the submission of an application for marketing approval of DS-5670 to the regulatory authorities in Japan. DS-5670 is an mRNA vaccine, being developed against…
Read More...

Takeda announced that EXKIVITY (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced…
Read More...

On January 6, 2023, Health Canada approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast…
Read More...

Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty…
Read More...

Myrtelle Inc., a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and rAAVen Therapeutics, (“rAAVen”) an AAV…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of…
Read More...

PreveCeutical Medical Inc. is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH (“Endosane”), a subsidiary of Sanity Group,…
Read More...

Solid Biosciences Inc. and Phlox Therapeutics announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic…
Read More...

Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announces that…
Read More...

Syneos Health announced a strategic partnership with Fosun Pharma USA Inc., the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. As part of the partnership, Syneos…
Read More...

AbbVie and Anima Biotech announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning…
Read More...

UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announced that the US…
Read More...

BioNTech SE and InstaDeep Ltd. announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of…
Read More...

Alora Pharmaceuticals, LLC, is pleased to announce that its wholly owned subsidiary, Sovereign Pharmaceuticals, LLC, has acquired, through bankruptcy proceedings, substantially all of…
Read More...

JanOne Inc., a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced that it has completed the acquisition of Soin Therapeutics, LLC…
Read More...

Servier and Aqemia announce the extension of their new-molecule discovery collaboration on an undruggable therapeutic target in immuno-oncology. This extension follows Servier and…
Read More...

Selecta Biosciences, Inc. and Astellas Pharma Inc. announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation…
Read More...

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments…
Read More...

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced it has signed a multi-year research…
Read More...

Boehringer Ingelheim and 3T Biosciences, announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to…
Read More...